Regeneron beats Q2 expectations on Dupixent, high-dose Eylea

1. 1Regeneron (REGN) beats Q2 revenue and earnings expectations on strong Dupixent and high-dose Eylea
2. 2Revenue $4.29B, adjusted EPS $14.29; Dupixent net sales reach approximately $6B
3. 3RBC expects improved H2 results on solid commercial performance and margin improvement from Sanofi development balance repayment

Source Reuters · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →